A study using albino cane toads with edited genes challenges the belief that albino wildlife is rare because it’s more ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...
In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...
CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...
From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
Investor's Business Daily on MSN
Why Gene-Editing Giants Crispr And Intellia Just Surged
At American Heart Association conference in New Orleans, Crispr Therapeutics CRSP said a single dose of its gene-editing drug ...
An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...
The company scans entire proteins with CRISPR to find functional vulnerabilities, then hunts for molecules that exploit them ...
CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and fat storage. Preclinical studies showed strong metabolic benefits, ...
Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback